Staar Surgical Co (NAS:STAA)
$ 37.23 3.36 (9.92%) Market Cap: 1.83 Bil Enterprise Value: 1.63 Bil PE Ratio: 109.50 PB Ratio: 4.47 GF Score: 85/100
Back to the Transcripts List

Q1 2024 STAAR Surgical Co Earnings Call Transcript

May 07, 2024 / 08:15PM GMT
Release Date Price: $46.65 (+1.46%)

Key Points

Positve
  • STAAR Surgical Co (STAA) reported a net sales of $77.4 million for Q1 2024, exceeding expectations and demonstrating strong year-over-year growth.
  • The company achieved a 21% sequential sales growth in the U.S., reaching record quarterly U.S. ICL sales of $5 million.
  • STAAR Surgical Co (STAA) saw significant growth in the Asia Pacific region with a 9% increase, including a 10% growth in China, surpassing the full year fiscal 2024 outlook of 7%.
  • The EMEA region experienced an 11% sales growth, driven by strong performance in the Middle East and European distributor markets.
  • STAAR Surgical Co (STAA) introduced several new initiatives such as the Star University and the Stellar ordering and planning system, enhancing surgeon efficiency and expanding educational resources.
Negative
  • Despite overall growth, the company reported a net loss of $3.3 million for Q1 2024, attributed mainly to a $2.3 million loss related to foreign currency exchange.
  • Operating expenses for Q1 2024 increased significantly to $63.3 million compared to $54.8 million in the prior year, reflecting higher investments to build the market for EVO ICL.
  • Gross margin saw a slight decline sequentially from Q4 2023, primarily due to inventory adjustments.
  • The company faces ongoing challenges in a dynamic macroeconomic and geopolitical environment, which could impact consumer discretionary spending and overall market conditions.
  • STAAR Surgical Co (STAA) is experiencing increased competition in key markets, particularly with the anticipated entry of local lens competitors in China.
Operator

Greetings, and welcome to the STAAR Surgical first-quarter 2024 earnings call and webcast. (Operator Instructions) Please note this call is being recorded today, Tuesday, May 7, 2024.

I would now like to turn the call over to Brian Moore, Vice President of Investor Relations at STAAR Surgical. Please go ahead.

Brian Moore
STAAR Surgical Co - Investor Relation, Vice President, Media Relations, Corporate Development

Thank you, operator. Good afternoon, everyone, and thank you for joining us to discuss the company's financial results for the first quarter ended March 29, 2024. On the call today are Tom Frinzi, President and Chief Executive Officer; and Patrick Williams, Chief Financial Officer.

The press release of our first quarter results was issued just after 4:00 PM Eastern Time. We have posted the earnings release and our earnings presentation supplement to the Investor Relations section of STAAR's website at www.staar.com.

Before we begin, let me quickly remind you

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.